viewSkinBioTherapeutics PLC

SkinBioTherapeutics raises £4mln to accelerate development

As well as a placing at 16p a share, the firm has organised an open offer of stock that could bring in an additional £500,000

SkinBioTherapeutics PLC -

SkinBioTherapeutics PLC (LON:SBTX) has raised £4mln from existing and new institutions that will help fund work on new product applications for its technology and will also be used to expand its research and development capabilities.

Up to a further £500,000 could be banked from an open offer of stock to current shareholders not involved in the placing.

The proceeds of the fundraisers will be deployed to explore other uses for SkinBiotix - which harnesses the power of the microbiome found on the skin – in oral and hair indications.

It will also be invested to expand the group’s research capabilities by adding its own facilities to those it uses at the University of Manchester.

SkinBioTherapeutics said it also wants to explore both the launch of an own-label cosmetic product and further partnering opportunities.

Last year the company struck a deal with speciality chemicals giant Croda, which is using the SkinBioTherapeutics-developed active ingredient in cosmetics.

It also has an agreement with a company called Winclove to develop a food supplement to treat the symptoms of psoriasis.

“Both development tracks are making great progress,” SkinBio chief executive Stuart Ashman said in a statement.

"The new funds will help accelerate the development of other areas for our technology - for example in oral care and in hair, whilst we continue to progress our human study in psoriasis. We will also be able to strengthen our R&D resources, infrastructure and team, which have, until now, been kept minimal.

"We are entering an exciting chapter for the company into one of late-stage development and commercialisation, whilst continuing to broaden the microbiome base of the company."

Quick facts: SkinBioTherapeutics PLC


Price: 57 GBX

Market Cap: £89.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


SkinBioTherapeutics' all set for launch of psoriasis treatment in fourth quarter

SkinBioTherapeutics PLC (AIM:SBTX, FRA:5KW)'s (AIM:SBTX, FRA:5KW) (LON:SBTX) Stuart Ashman talks to Proactive London about the plan for their psoriasis treatment ahead of their fourth quarter commercial launch.  He explains how the most recent findings have found that it can be used for other...

on 19/8/21

2 min read